Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 387-392

  Sonabend, Rona Y ^a,b   McKay, Siripoom V ^a   Okcu, M Fatih ^a   Yan, Jinrong ^a   Haymond, Morey W ^a   Margolin, Judith F ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Texas Children's Hospital   (United States)

Author keywords

Acute lymphoblastic leukemia; Cancer; Child; Complications; Hyperglycemia; Infections; Steroids

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; GLUCOSE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BACTEREMIA; CELLULITIS; CHILD; CONTROLLED STUDY; FEMALE; FEVER; FUNGEMIA; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; OBESITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADOLESCENT; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERGLYCEMIA; INFECTION; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREVALENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 48249150746     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21624     Document Type: Article

References (26)

1. Carroll WL, Bhojwani D, Min DJ, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003;102-131.
2. Devos P, Preiser JC. Tight blood glucose control: A recommendation applicable to any critically ill patient? Crit Care 2004;8:427-429.
3. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. J Pediatr 2005;146:30-34.
4. Srinivasan V, Spinella PC, Drott HR, et al. Association of timing, duration, and intensity of hyperglycemia with intensive care unit mortality in critically ill children. Pediatr Crit Care Med 2004;5:329-336.
5. Ali NA, O'Brien JM, Jr., Blum W, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer 2007;110:96-102.
6. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: A meta-analysis of randomized controlled trials. Arch Intern Med 2004;164:2005-2011.
7. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367.
8. Vanhorebeek I, Langouche L, Van den Berghe G. Glycemic and nonglycemic effects of insulin: How do they contribute to a better outcome of critical illness? Curr Opin Crit Care 2005;11:304-311.
9. Egi M, Bellomo R, Stachowski E, et al. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244-252.
10. Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues 2006;17:50-55.
11. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004;30:748-756.
12. Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. J Med 1994;25:219-229.
13. Baillargeon J, Langevin AM, Lewis M, et al. Demographic correlates of body size changes in children undergoing treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer 2007;49: 793-796.
14. Baillargeon J, Langevin AM, Lewis M, et al. Obesity and survival in a cohort of predominantly hispanic children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2006;28:575-578.
15. Baillargeon J, Langevin AM, Mullins J, et al. Transient hyperglycemia in hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2005;45:960-963.
16. Neville KA, Cohn RJ, Steinbeck KS, et al. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: Prevalence and risk factors. J Clin Endocrinol Metab 2006;91:4401-4407.
17. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100:1179-1185.
18. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 2003;26:S5-S20.
20. Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diab Care 2000;23:1108-1112.
21. Pui CH, Burghen GA, Bowman WP, et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981;99:46-50.
22. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. Adults. The third national health and nutrition examination survey, 1988-1994. Diab Care 1998;21:518-524.
23. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The hoorn study. JAMA 2001;285:2109-2113.
24. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004; 164:2090-2095.
25. Asensio C, Muzzin P, Rohner-Jeanrenaud F. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int J Obes Relat Metab Disord 2004;28:S45-S52.
26. Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes 2003;52: 1475-1484.